WO2008070672A3 - Compositions and methods to treat cancer with cupredoxins and cpg rich dna - Google Patents

Compositions and methods to treat cancer with cupredoxins and cpg rich dna Download PDF

Info

Publication number
WO2008070672A3
WO2008070672A3 PCT/US2007/086393 US2007086393W WO2008070672A3 WO 2008070672 A3 WO2008070672 A3 WO 2008070672A3 US 2007086393 W US2007086393 W US 2007086393W WO 2008070672 A3 WO2008070672 A3 WO 2008070672A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
cancer
aeruginosa
present
Prior art date
Application number
PCT/US2007/086393
Other languages
French (fr)
Other versions
WO2008070672A2 (en
Inventor
Gupta Tapas Das
Ananda Chakrabarty
Original Assignee
Univ Illinois
Gupta Tapas Das
Ananda Chakrabarty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Gupta Tapas Das, Ananda Chakrabarty filed Critical Univ Illinois
Priority to MX2009005849A priority Critical patent/MX2009005849A/en
Priority to JP2009540425A priority patent/JP2010511408A/en
Priority to BRPI0718360-7A2A priority patent/BRPI0718360A2/en
Priority to EP07868980A priority patent/EP2089411A4/en
Priority to CA002671492A priority patent/CA2671492A1/en
Priority to AU2007329375A priority patent/AU2007329375A1/en
Publication of WO2008070672A2 publication Critical patent/WO2008070672A2/en
Publication of WO2008070672A3 publication Critical patent/WO2008070672A3/en
Priority to NO20092522A priority patent/NO20092522L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compositions comprising CpG rich DNA from Pseudomonas aeruginosa. The compositions optionally comprise a cupredoxin. The present invention includes specific CpG DNAs from Pseudomonas aeruginosa that are useful for treating cancer and other conditions in patients. These compositions are optionally in a pharmaceutically acceptable carrier and also optionally comprise a cupredoxin. The present invention further relates to methods to express proteins near cancer cells. These methods may be used to express therapeutic or diagnostic proteins near cancer cells in a patient suffering from cancer or other conditions, and can also be used for diagnosing cancer in a patient. This method uses the gene for azurin from P. aeruginosa as an expression system for azurin or heterologous proteins in P. aeruginosa or heterologous cells.
PCT/US2007/086393 2006-12-04 2007-12-04 Compositions and methods to treat cancer with cupredoxins and cpg rich dna WO2008070672A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MX2009005849A MX2009005849A (en) 2006-12-04 2007-12-04 Compositions and methods to treat cancer with cupredoxins and cpg rich dna.
JP2009540425A JP2010511408A (en) 2006-12-04 2007-12-04 Compositions and methods for treating cancer with CpG rich DNA and cupredoxins
BRPI0718360-7A2A BRPI0718360A2 (en) 2006-12-04 2007-12-04 "COMPOSITIONS AND METHODS FOR CANCER TREATMENT WITH COUPREDOXINS AND RICH DNA IN CPG"
EP07868980A EP2089411A4 (en) 2006-12-04 2007-12-04 Compositions and methods to treat cancer with cupredoxins and cpg rich dna
CA002671492A CA2671492A1 (en) 2006-12-04 2007-12-04 Compositions and methods to treat cancer with cupredoxins and cpg rich dna
AU2007329375A AU2007329375A1 (en) 2006-12-04 2007-12-04 Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
NO20092522A NO20092522L (en) 2006-12-04 2009-07-03 Compositions and Methods for Treating Cancer with Cupredoxins and CPG Rich DNA

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87247106P 2006-12-04 2006-12-04
US60/872,471 2006-12-04

Publications (2)

Publication Number Publication Date
WO2008070672A2 WO2008070672A2 (en) 2008-06-12
WO2008070672A3 true WO2008070672A3 (en) 2009-04-16

Family

ID=39493039

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/086393 WO2008070672A2 (en) 2006-12-04 2007-12-04 Compositions and methods to treat cancer with cupredoxins and cpg rich dna
PCT/US2007/086385 WO2008070666A2 (en) 2006-12-04 2007-12-04 Compositions and methods to treat cancer with cpg rich dna and cupredoxins

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086385 WO2008070666A2 (en) 2006-12-04 2007-12-04 Compositions and methods to treat cancer with cpg rich dna and cupredoxins

Country Status (12)

Country Link
US (3) US8017749B2 (en)
EP (1) EP2089411A4 (en)
JP (2) JP2010511408A (en)
KR (1) KR20090095626A (en)
CN (1) CN101600728A (en)
AU (1) AU2007329375A1 (en)
BR (1) BRPI0718360A2 (en)
CA (1) CA2671492A1 (en)
MX (1) MX2009005849A (en)
NO (1) NO20092522L (en)
RU (1) RU2009125599A (en)
WO (2) WO2008070672A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7381701B2 (en) * 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US8114418B2 (en) * 2001-06-21 2012-02-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—IV
SI2241325T1 (en) * 2002-10-29 2012-05-31 Coley Pharm Group Inc Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
EP1663316A2 (en) * 2003-09-25 2006-06-07 Coley Pharmaceutical Group, Inc. Nucleic acid lipophilic conjugates
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
UA97466C2 (en) * 2004-10-07 2012-02-27 Ананда Чакрабарти Cupredoxin derived transport agents and methods of use thereof
JP2010511408A (en) * 2006-12-04 2010-04-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for treating cancer with CpG rich DNA and cupredoxins
JP2010518123A (en) * 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for preventing cancer with cupredoxins
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
NZ593220A (en) 2008-12-09 2012-10-26 Coley Pharm Group Inc Immunostimulatory oligonucleotides
WO2014049604A2 (en) * 2012-09-05 2014-04-03 Amrita Therapeutics Limited A novel biomedical device for cancer therapy
CA2895457A1 (en) * 2012-12-21 2014-06-26 Teva Pharmaceutical Industries Ltd. Oral transmucosal delivery of glatiramer acetate
EP3115039B1 (en) * 2015-07-09 2021-12-15 beniag GmbH Method for producing a fusion mixture for transferring a charged molecule into and/or through a lipid membrane
RU204475U1 (en) * 2020-09-24 2021-05-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт медицины труда имени академика Н.Ф. Измерова" (ФГБНУ "НИИ МТ") Medical applicator for topical treatment of skin diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018662A1 (en) * 2003-08-15 2005-03-03 Board Of Trustees Of The University Of Illinois Use of polypeptides of the cupredoxin family in cancer therapy
US20060149037A1 (en) * 2004-10-07 2006-07-06 Ananda Chakrabarty Cupredoxin derived transport agents and methods of use thereof
US7084105B2 (en) * 2001-02-15 2006-08-01 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
WO2007024368A2 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
US7381701B2 (en) * 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6167490A (en) * 1984-09-07 1986-04-07 Sagami Chem Res Center Cyclic double-chain dna having pl promoter
US4817384A (en) 1986-08-13 1989-04-04 Toyota Jidosha Kabushiki Kaisha Double air-fuel ratio sensor system having improved exhaust emission characteristics
US5567411A (en) 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
US5252317A (en) 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
DE4138042C2 (en) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilones, their production processes and agents containing these compounds
US5760191A (en) 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
US5417959A (en) 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
US5520904A (en) 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
EP0727225A3 (en) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasound imaging
US5801228A (en) 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
PT1186606E (en) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf DERIVATIVES OF THE EPOTILONE ITS PREPARATION AND UTILIZATION
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5804161A (en) 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
JP2001508762A (en) 1996-06-27 2001-07-03 ジー．ディー．サール アンド カンパニー Particles consisting of an amphiphilic copolymer having a cross-linked outer shell region and inner core region, useful for pharmaceutical and other applications
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US7807182B2 (en) 1996-12-31 2010-10-05 Colorado State University Research Foundation Early detection of mycobacterial disease using peptides
CN1544436A (en) 1997-02-25 2004-11-10 ���＼���о����޹�˾��GBF�� Process for the preparation of epothilone a and b n-oxides and the products obtained thereby
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
WO1999002224A1 (en) 1997-07-07 1999-01-21 Lewis Robert D Statistical analysis and feedback system for sports employing a projectile
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP1001951B1 (en) 1997-07-16 2002-09-25 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
FR2766185B1 (en) 1997-07-18 2001-06-15 Rhone Poulenc Rorer Sa MEDICINAL PRODUCTS CONTAINING AS AT LEAST ONE SUBSTITUTED POLYHYDROXYLALKYLPYRAZINE DERIVATIVE, THE NEW POLYHYDROXYLALKYLPYRAZINE DERIVATIVES AND THEIR PREPARATION
ATE368036T1 (en) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag NEW EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE
IT1297288B1 (en) 1997-10-31 1999-09-01 Denis Robert Gemmani SERRATED METAL GRATING STRUCTURE PARTICULARLY FOR THE COMPLETION OF PRODUCTS AND BUILDING WORKS FOR CIVIL OR INDUSTRIAL USE
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
WO1999043653A1 (en) 1998-02-25 1999-09-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
DE19826988A1 (en) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone minor components
WO1999067253A2 (en) 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
WO2000000485A1 (en) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
US7556810B2 (en) * 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7618939B2 (en) * 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7301010B2 (en) * 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US7338766B2 (en) * 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7338776B2 (en) 2002-03-20 2008-03-04 Jcr Pharmaceuticals Co., Ltd. Production of UGPPase
KR100456681B1 (en) * 2002-05-22 2004-11-10 주식회사 대웅 Immnune-stimulating and controlling Composition comprising bacterial chromosomal DNA fragments and detoxified lipopolysaccharides
CN1506375A (en) * 2002-12-12 2004-06-23 浙江养生堂天然药物研究所有限公司 Azurin as bacterial protein with wide-spectrum antitumor function and its use and medicinal composition
CN100486987C (en) 2003-03-05 2009-05-13 长春华普生物技术有限公司 Antivira and antitumor deoxyoligonucleotide containing CpG single strand
US7807183B2 (en) * 2005-07-19 2010-10-05 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
US10675326B2 (en) * 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US20090208476A1 (en) * 2006-05-19 2009-08-20 Tapas Das Gupta Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
US10005821B2 (en) * 2004-10-07 2018-06-26 The Board Of Trustees Of The University Of Illinois Modifications of cupredoxin derived peptides and methods of use thereof
US9968685B2 (en) * 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US8158574B2 (en) * 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
JP2008545398A (en) * 2005-05-20 2008-12-18 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for treating HIV infection using cupredoxin and cytochrome C
JP4582004B2 (en) * 2006-01-13 2010-11-17 セイコーエプソン株式会社 LIGHT EMITTING DEVICE AND ELECTRONIC DEVICE
US20140287990A1 (en) * 2006-05-19 2014-09-25 The Board Of Trustees Of The University Of Illinois Compositions and methods to concurrently treat and/or prevent multiple diseases with cupredoxins
US10266868B2 (en) * 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
KR100801002B1 (en) * 2006-06-05 2008-02-11 삼성전자주식회사 Method for transferring/playing multimedia data on wireless network and wireless device thereof
CN101595124A (en) * 2006-09-14 2009-12-02 伊利诺斯大学理事会 Use the composition and the method for cupredoxin preventing cancer
WO2008066658A2 (en) * 2006-11-03 2008-06-05 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
JP2010511408A (en) * 2006-12-04 2010-04-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for treating cancer with CpG rich DNA and cupredoxins
JP2010518123A (en) * 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for preventing cancer with cupredoxins
WO2009078977A2 (en) * 2007-12-14 2009-06-25 Cdg Therapeutics Inc Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
US9624277B2 (en) * 2010-10-01 2017-04-18 Amrita Therapeutics Limited Anticancer agent
AU2012232965B2 (en) * 2011-09-30 2015-07-09 Elaflex Hiby Tanktechnik Gmbh & Co. Dispensing Valve
WO2017012661A1 (en) * 2015-07-22 2017-01-26 Curetis Gmbh Genetic testing for predicting resistance of pseudomonas species against antimicrobial agents
KR102024186B1 (en) * 2017-05-04 2019-09-23 주식회사 젠센 Peptide for inhibiting toll-like receptors and pharmaceutical composition comprising the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084105B2 (en) * 2001-02-15 2006-08-01 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US20060292136A1 (en) * 2001-02-15 2006-12-28 Chakrabarty Ananda M Cytotoxic factors for modulating cell death
US7381701B2 (en) * 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
WO2005018662A1 (en) * 2003-08-15 2005-03-03 Board Of Trustees Of The University Of Illinois Use of polypeptides of the cupredoxin family in cancer therapy
US20060149037A1 (en) * 2004-10-07 2006-07-06 Ananda Chakrabarty Cupredoxin derived transport agents and methods of use thereof
WO2007024368A2 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
MAHFOUZ. M. ET AL.: "Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy.", PLASMID., vol. 57, 2007, pages 4 - 17, XP005734316 *
PUNJ. V. ET AL.: "Bacterial cupredoxin azurin and its interactions with the tumor suppressor protein p53.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 312, 2003, pages 109 - 114, XP004473236 *
PUNJ. V. ET AL.: "Bacterial cupredoxin azurin as a inducer of apoptosis and regression in huamn breast cancer.", ONCOGENE, vol. 23, 2004, pages 2367 - 2378, XP003018759 *
PUNJ. V. ET AL.: "Microbial-based therapy of cancer.", CANCER BIOLOGY AND THERAPY., vol. 3, no. 8, August 2004 (2004-08-01), pages 708 - 714, XP009088757 *
See also references of EP2089411A4 *
WU. H.J. ET AL.: "Azurin of pathogenic Neisseria ssp. is involved in defense against hydrogen peroxide and survival within cervical epithelial cells.", INFECTION AND IMMUNITY., vol. 73., December 2005 (2005-12-01), pages 8444 - 8448, XP008109842 *
YAMADA. T. ET AL.: "Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.", PNAS., vol. 99, no. 22, 29 October 2002 (2002-10-29), pages 14098 - 14103, XP002486971 *
YAMADA. T. ET AL.: "Intemalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity.", CELLULAR MICROBIOLOGY., vol. 7, no. 10, 2005, pages 1418 - 1431, XP002499203 *

Also Published As

Publication number Publication date
US8017749B2 (en) 2011-09-13
WO2008070666A2 (en) 2008-06-12
RU2009125599A (en) 2011-01-20
US20120014877A1 (en) 2012-01-19
BRPI0718360A2 (en) 2013-11-12
CN101600728A (en) 2009-12-09
CA2671492A1 (en) 2008-06-12
US20200172581A1 (en) 2020-06-04
AU2007329375A1 (en) 2008-06-12
JP2014158486A (en) 2014-09-04
US20090226405A1 (en) 2009-09-10
EP2089411A2 (en) 2009-08-19
US9969781B2 (en) 2018-05-15
EP2089411A4 (en) 2010-01-27
WO2008070666A3 (en) 2009-04-09
JP2010511408A (en) 2010-04-15
NO20092522L (en) 2009-09-04
MX2009005849A (en) 2009-08-12
WO2008070672A2 (en) 2008-06-12
US11046733B2 (en) 2021-06-29
KR20090095626A (en) 2009-09-09
AU2007329375A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
WO2008070672A3 (en) Compositions and methods to treat cancer with cupredoxins and cpg rich dna
WO2007011363A3 (en) Binding domain fusion proteins
WO2008060510A3 (en) Zinc finger nuclease for targeting the human glucocorticoid receptor locus
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2007007173A3 (en) Human anti-madcam antibodies
MA33717B1 (en) TARGETED IMMUNOCONJUGATES
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
EP2308885A3 (en) Novel compounds and methods for therapy
WO2005027839A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2008050148A3 (en) Therapy for liver disease
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2006002262A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2009106819A3 (en) Biological materials and uses thereof
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2007101063A3 (en) Treatment of development-related disorders
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
WO2006116185A3 (en) Methods for the treatment of multiple myeloma

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780050577.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868980

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1058/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2671492

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007329375

Country of ref document: AU

Ref document number: 577412

Country of ref document: NZ

Ref document number: MX/A/2009/005849

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009540425

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007868980

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097013765

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007329375

Country of ref document: AU

Date of ref document: 20071204

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009125599

Country of ref document: RU

Kind code of ref document: A

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0718360

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090602